ArticleJMA journal2026
Leucine-Rich α2 Glycoprotein as a Predictor of Small Bowel Disease Activity in Crohn's Disease: A Retrospective Study.
Article in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Balloon-assisted enteroscopy is the gold standard for evaluating small bowel lesions in Crohn's disease (CD); however, its invasiveness and cost limit routine use. Leucine-rich α-2 glycoprotein (LRG) has emerged as a potential noninvasive biomarker. This study aimed to assess the diagnostic utility of LRG compared with conventional biomarkers. Methods: This retrospective study included 216 patients with CD who underwent balloon-assisted enteroscopy between April 2021 and March 2024. Serum biomarkers, including LRG, C-reactive protein, leukocyte count, neutrophil count, hemoglobin, platelet count, erythrocyte sedimentation rate, and albumin, were analyzed. Endoscopic activity was defined as mucosal ulcers measuring ≥0.5 cm. Diagnostic performance was evaluated using receiver operating characteristic curve analysis, and predictors of endoscopic activity were identified using multivariate logistic regression. Prognostic value was assessed using hospitalization-free and surgery-free survival. Results: LRG demonstrated the highest diagnostic accuracy (area under the ROC curve (AUC), 0.906), outperforming C-reactive protein ( area under the receiver operating characteristic curve: 0.776). An LRG cutoff of 16.3 μg/mL yielded 72.1% sensitivity and 93.7% specificity. Elevated LRG was independently associated with endoscopic activity (odds ratio: 36.4, p < 0.001) and correlated with higher modified Simple Endoscopic Score for Crohn's disease (mSES-CD). High LRG levels were also predictive of poorer hospitalization-free and surgery-free survival. Conclusions: LRG is a reliable and non-invasive biomarker for assessing small bowel disease activity in CD, showing superior diagnostic and prognostic performance compared with conventional biomarkers. It may be a valuable adjunct to endoscopic and imaging evaluations in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.